Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$68.04 USD
-0.08 (-0.12%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $68.04 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.04 USD
-0.08 (-0.12%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $68.04 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth C Momentum C VGM
Zacks News
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for GSEW
Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?
by Zacks Equity Research
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts Believe Exact Sciences (EXAS) Could Rally 34.33%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Exact Sciences (EXAS) points to a 34.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
EW Stock Dips Following the Divestiture of Critical Care Wing
by Zacks Equity Research
Edwards completes the sale of its Critical Care operations and announces a $1 billion share repurchase program.
Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for GSEW
EW Stock to Benefit From Favorable RHEIA Trial Data on TAVI
by Zacks Equity Research
Edwards' first all-female TAVI Trial demonstrates favorable outcomes for women receiving Edwards valves.
Exact Sciences (EXAS) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN and AstraZeneca Expand Pact to Develop CDx in Chronic Diseases
by Zacks Equity Research
QGEN's expanded collaboration with AstraZeneca to focus on developing companion diagnostics beyond oncology.
Boston Scientific's ACURATE Prime Aortic Valve System Wins CE Mark
by Zacks Equity Research
BSX achieves CE Mark approval for the ACURATE Prime Aortic Valve System, its latest TAVR technology.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
ILMN's TSO Comprehensive IVD Test Secures FDA Approval as CDx
by Zacks Equity Research
Illumina's cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted therapies.
Abbott's Core Businesses Thrive Despite Macroeconomic Issues
by Zacks Equity Research
ABT is particularly gaining from the strong adoption of its market leading systems and demand for testing that takes place in a variety of settings.
Verano Expands U.S. Cannabis Footprint With New Buyouts
by Zacks Equity Research
This deal helps VRNOF foray into the Virginia market ahead of the Adult Use Program launch and will deepen the company's footprint in Arizona cannabis market.
Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes
by Zacks Equity Research
PODD marks a major milestone with Omnipod 5 approval for the treatment of type 2 diabetes.
What Role Will Macro Data Play, Before the U.S. Election?
by John Blank
In other words, can U.S. macro data trump any U.S election uncertainty?
Does Exact Sciences (EXAS) Have the Potential to Rally 34.13% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.1% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches
by Zacks Equity Research
Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.
Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study
by Zacks Equity Research
Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as the primary study sites.
Why You Should Add Exact Sciences (EXAS) to Your Portfolio
by Zacks Equity Research
Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.
The Zacks Analyst Blog Highlights Nomura Research Institute, Manhattan Associates and Exact Sciences
by Zacks Equity Research
Nomura Research Institute, Manhattan Associates and Exact Sciences are part of the Zacks top Analyst Blog.
Volatility Stays with Markets: Global Week Ahead
by John Blank
Investors should have learned by now that there's no such thing as a "quiet" summer in the markets. A year ago, bond yields rose sharply on worries about the U.S. fiscal outlook. The summer before, inflation and rate hike fears jolted markets.
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.